Dipak Das, the UConn red wine researcher charged by his institution with rampant misconduct that will likely lead to dozens of retractions, is evidently a 99%-er — when it comes to accuracy, that is. According to a statement purportedly from his lawyer refuting those charges, Das claims, among other things, that the output from his … Continue reading Resveratrol researcher Dipak Das: My lab’s work was “99% correct”
In the wake of the massive allegations of fraud by resveratrol researcher Dipak Das, other researchers in the field are clearly trying to distance themselves from the University of Connecticut scientist. Nir Barzilai told us yesterday, for example, that despite Das seemingly’ impressive publication record, “Rome was not built on Dr. Das.” Harvard’s David Sinclair went … Continue reading So how peripheral was Dipak Das’ resveratrol work, really?
The University of Connecticut, in what clearly seems like an attempt to get ahead of damaging news, has announced an “extensive” investigation into research misconduct involving one of its scientists, Dipak K. Das. According to a press release, the university has notified 11 journals that published Das’ work about the alleged fraud. One area of … Continue reading UConn resveratrol researcher Dipak Das fingered in sweeping misconduct case
The authors of a study in Urology that was at the center of two 2009 lawsuits brought by a company that funded the work have retracted the paper. The idea behind the research — by Robert Getzenberg and colleagues at Johns Hopkins — was to find an alternative to the prostate specific antigen (PSA) test, … Continue reading Hopkins scientists retract prostate cancer screening study at center of 2009 lawsuits
If Retraction Watch was actually a business, as opposed — for the moment, anyway — to a labor of love for two guys with day jobs, 2011 would have been a very good year for business. It was a year that will probably see close to 400 retractions, including a number of high-profile ones, once … Continue reading The Year of the Retraction: A look back at 2011
More than 14 months after Blood issued a notice of concern about a paper by a Harvard stem cell scientist and her former post-doc, the journal has retracted the article. Here’s the notice for the paper, “Osteolineage niche cells initiate hematopoietic stem cell mobilization,” by Shane Mayack and Amy Wagers:
The senior author of a Journal of Immunology paper has retracted it after a university investigation found that he had inappropriately manipulated images, Retraction Watch has learned. Here’s the notice:
An HIV researcher in Germany has run afoul of a number of journals because he duplicated his papers in multiple outlets. The funny business by Ulrich Hengge earned him a 3-year ban on publishing in two journals, the Journal of Molecular Medicine (JMM) and Cells, Tissues and Organs (CTO). (We’ve written about publishing bans — which … Continue reading Duplication earns German HIV researchers a retraction, and a 3-year publishing ban
PLoS One and Nature Medicine have issued corrections for papers by Zhiguo Wang, the former Montreal Heart Institute researcher who resigned in September following an investigation into image manipulation in his lab. In September, PLoS One told us that they were investigating the paper. Here’s the text of the correction for “Transcriptional and Post-Transcriptional Mechanisms for Oncogenic Overexpression of … Continue reading Corrections in PLoS One, Nature Medicine for Zhiguo Wang, and details about Montreal Heart Institute investigation
A retraction notice appeared a few months ago in the Biophysical Journal: This article has been retracted: please see Elsevier Policy on Article Withdrawal (http://www.elsevier.com/locate/withdrawalpolicy). This article has been retracted at the request of Edward Egelman, Editor-in-Chief. The editors have noted that there is a substantial overlap of figures and text between this Biophysical Journal … Continue reading Why editors should stop ignoring anonymous whistleblowers: Our latest LabTimes column